体内CAR-T赛道白热化:盘点国内19家核心企业管线全景图

求实药社
Dec 18, 2025

跨国药企重磅加注,国内Biotech加速推进,体内CAR-T已成细胞治疗领域的热门赛道。这项颠覆性技术旨在解决传统CAR-T高成本、长周期的痛点,并进一步拓展血液瘤、实体瘤及自免疾病适应症。中国力量正以自主研发+国际协同双线突围,在全球竞速中抢占先机。纵观国内研发格局,体内CAR-T正呈现出“技术路线多元化”与“临床验证加速化”的双重特征。在递送载体方面,赛道已分化为两大阵营:一是以上海易慕峰、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10